Cancer Genetics bounces on sale of biopharma business

Interpace Biosciences

16/07/2019 11:30

** Diagnostics co Cancer Genetics  CGIX.O  up 73.2% at $0.30
after co announces sale of its biopharma business to peer
Interpace Diagnostics Group  IDXG.O       
    ** CGIX is top gainer premarket among Nasdaq-listed stocks
and is set for its best day since its debut in 2013; IDXG flat
premarket
    ** CGIX says gross purchase price is $23.5 mln in addition
to assumption by IDXG of about $5 mln of liabilities
 urn:newsml:reuters.com:*:nGNX7kZ40y
    ** Co also says Clinical Services Business acquired by
Siparadigm Diagnostic Informatics
    ** CGIX last traded at current levels at over three months
ago
    ** Up to Monday's close CGIX down ~28% YTD; IDXG down 12.6%

 (Reporting by Uday Sampath in Bengaluru)
 ((Reuters Messaging:
UdaySampath.Kumar.thomsonreuters.com@reuters.net))